 |
20 Diseases |  |
29 Trials |
|
29 Trials |  |
1253 News |  |
| «12...891011121314151617181920» |
- | Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
New P4 trial: TEMPO: A TEst and Treat Intervention aMong Current People Who Inject Drugs With HCV Attending Needle and Syringe PrOgrams (clinicaltrials.gov) - Apr 10, 2018
P4, N=300, Not yet recruiting, Sponsor: Kirby Institute
- | sofosbuvir/velpatasvir / Generic mfg.
Trial completion date, Trial initiation date, Trial primary completion date: HCV Post-Exposure Prophylaxis for Health Care Workers (clinicaltrials.gov) - Mar 29, 2018
P4, N=60, Not yet recruiting, Sponsor: Massachusetts General Hospital
Trial completion date: Jul 2021 --> Jul 2022 | Initiation date: Jan 2018 --> Jul 2018 | Trial primary completion date: Dec 2020 --> Dec 2021
- | sofosbuvir/velpatasvir / Generic mfg.
Phase classification: Expanding the Pool in Orthotopic Heart Transplantation (clinicaltrials.gov) - Mar 26, 2018
P, N=100, Recruiting, Sponsor: University of Pittsburgh
Trial completion date: Jul 2021 --> Jul 2022 | Initiation date: Jan 2018 --> Jul 2018 | Trial primary completion date: Dec 2020 --> Dec 2021 Phase classification: P=N/A --> P
- | sofosbuvir/velpatasvir / Generic mfg.
Enrollment open: TROJAN-C: Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients (clinicaltrials.gov) - Mar 23, 2018
P2, N=20, Recruiting, Sponsor: Baylor Research Institute
Phase classification: P=N/A --> P Not yet recruiting --> Recruiting
- | sofosbuvir/velpatasvir / Generic mfg.
Enrollment open: Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection (clinicaltrials.gov) - Mar 9, 2018
P4, N=75, Recruiting, Sponsor: Elizabeth Krans, MD
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| sofosbuvir/velpatasvir / Generic mfg.
Enrollment closed, Enrollment change: GS-US-342-4062: Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease (clinicaltrials.gov) - Mar 9, 2018
P2, N=59, Active, not recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=100 --> 59
- ||||||| sofosbuvir/velpatasvir / Generic mfg.
Trial completion: GS-US-342-1521: Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection (clinicaltrials.gov) - Mar 9, 2018
P3, N=130, Completed, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting | N=100 --> 59 Active, not recruiting --> Completed
- | sofosbuvir/velpatasvir / Generic mfg.
Enrollment change, Trial completion date, Trial primary completion date: SToP-C: Surveillance and Treatment of Prisoners With Hepatitis C (clinicaltrials.gov) - Mar 7, 2018
P4, N=2500, Recruiting, Sponsor: Kirby Institute
Active, not recruiting --> Completed N=1200 --> 2500 | Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019
- |||| sofosbuvir/velpatasvir / Generic mfg.
Trial completion date, Trial primary completion date: Efficacy and Safety of Sofosbuvir/Velpatasvir (clinicaltrials.gov) - Mar 5, 2018
P3, N=102, Active, not recruiting, Sponsor: Gilead Sciences
N=1200 --> 2500 | Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019 Trial completion date: Jun 2018 --> May 2018 | Trial primary completion date: Mar 2018 --> Feb 2018
- | sofosbuvir/velpatasvir / Generic mfg.
Trial initiation date: Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection (clinicaltrials.gov) - Mar 3, 2018
P4, N=75, Not yet recruiting, Sponsor: Elizabeth Krans, MD
Trial completion date: Jun 2018 --> May 2018 | Trial primary completion date: Mar 2018 --> Feb 2018 Initiation date: Jan 2018 --> Feb 2018
- || sofosbuvir/velpatasvir / Generic mfg.
Trial completion date, Trial primary completion date: GS-US-342-4062: Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease (clinicaltrials.gov) - Mar 3, 2018
P2, N=100, Recruiting, Sponsor: Gilead Sciences
Initiation date: Jan 2018 --> Feb 2018 Trial completion date: Oct 2018 --> Nov 2018 | Trial primary completion date: Jul 2018 --> Aug 2018
- ribavirin / Generic mfg., sofosbuvir/velpatasvir / Generic mfg.
Trial completion date, Trial primary completion date: Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis (clinicaltrials.gov) - Feb 7, 2018
P2, N=50, Recruiting, Sponsor: Gilead Sciences
Trial completion date: Oct 2018 --> Nov 2018 | Trial primary completion date: Jul 2018 --> Aug 2018 Trial primary completion date: May 2018 --> Sep 2018 | Trial completion date: Aug 2018 --> Dec 2018
- || Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, Sovaldi (sofosbuvir) / Gilead
Trial completion date, Trial primary completion date: A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials (clinicaltrials.gov) - Feb 5, 2018
P=N/A, N=500, Enrolling by invitation, Sponsor: Gilead Sciences
Trial primary completion date: May 2018 --> Sep 2018 | Trial completion date: Aug 2018 --> Dec 2018 Trial primary completion date: Apr 2023 --> Sep 2027 | Trial completion date: Apr 2023 --> Sep 2027
- sofosbuvir/velpatasvir / Generic mfg.
Trial completion: Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation (clinicaltrials.gov) - Jan 26, 2018
P2, N=9, Completed, Sponsor: Gilead Sciences
Trial primary completion date: Apr 2023 --> Sep 2027 | Trial completion date: Apr 2023 --> Sep 2027 Active, not recruiting --> Completed
- | sofosbuvir/velpatasvir / Generic mfg.
Enrollment open: A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic (clinicaltrials.gov) - Jan 24, 2018
P4, N=20, Recruiting, Sponsor: Community Research Initiative of New England
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | sofosbuvir/velpatasvir / Generic mfg.
Phase classification: TROJAN-C: Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients (clinicaltrials.gov) - Jan 23, 2018
P2, N=20, Not yet recruiting, Sponsor: Baylor Research Institute
Not yet recruiting --> Recruiting Phase classification: P4 --> P2
- sofosbuvir/velpatasvir / Generic mfg.
Enrollment closed, Trial primary completion date: Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation (clinicaltrials.gov) - Jan 17, 2018
P2, N=9, Active, not recruiting, Sponsor: Gilead Sciences
Phase classification: P4 --> P2 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2018 --> Jan 2018
- | sofosbuvir/velpatasvir / Generic mfg.
New P4 trial: CRUSADE-1: Bioequivalence Study of Crushed Sofosbuvir/Velpatasvir Compared to the Whole Tablet (clinicaltrials.gov) - Jan 3, 2018
P4, N=14, Not yet recruiting, Sponsor: Radboud University
- | sofosbuvir/velpatasvir / Generic mfg.
New P2 trial, New P4 trial: TROJAN-C: Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients (clinicaltrials.gov) - Dec 26, 2017
P4, N=20, Not yet recruiting, Sponsor: Baylor Research Institute
- ||| sofosbuvir/velpatasvir / Generic mfg.
New P1 trial: Bioavailability and food effects of the pediatric formulation of SOF/VEL in adult subjects. (EUDRACT) - Dec 21, 2017
P1, N=194, , Sponsor: Gilead Sciences, Inc.
- | sofosbuvir/velpatasvir / Generic mfg.
New P1 trial: Expanding the Pool in Lung Transplantation (clinicaltrials.gov) - Dec 18, 2017
P1, N=100, Not yet recruiting, Sponsor: University of Pittsburgh
- | sofosbuvir/velpatasvir / Generic mfg.
Enrollment change: Generic VEL/SOF With or Without RBV for HIV/HCV Coinfected Patients (clinicaltrials.gov) - Dec 8, 2017
P4, N=228, Completed, Sponsor: National Taiwan University Hospital
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2018 --> Jan 2018 N=178 --> 228
- | sofosbuvir/velpatasvir / Generic mfg.
Trial initiation date: Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection (clinicaltrials.gov) - Nov 13, 2017
P4, N=75, Not yet recruiting, Sponsor: Elizabeth Krans, MD
N=178 --> 228 Initiation date: Sep 2017 --> Dec 2017
- | sofosbuvir/velpatasvir / Generic mfg.
Enrollment open, Post-transplantation: Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment (clinicaltrials.gov) - Oct 24, 2017
P4, N=10, Recruiting, Sponsor: Duke University
Initiation date: Sep 2017 --> Dec 2017 Not yet recruiting --> Recruiting
- |||| ribavirin / Generic mfg., sofosbuvir/velpatasvir / Generic mfg.
Trial completion: GS-US-342-2097: Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and Cirrhosis (clinicaltrials.gov) - Oct 20, 2017
P2, N=204, Completed, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | sofosbuvir/velpatasvir / Generic mfg.
New P4 trial: HCV Post-Exposure Prophylaxis for Health Care Workers (clinicaltrials.gov) - Oct 18, 2017
P4, N=60, Not yet recruiting, Sponsor: Massachusetts General Hospital
- ||||| sofosbuvir/velpatasvir / Generic mfg.
Enrollment closed: Efficacy and Safety of Sofosbuvir/Velpatasvir (clinicaltrials.gov) - Sep 26, 2017
P3, N=102, Active, not recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||||| sofosbuvir/velpatasvir / Generic mfg.
Trial completion: GS-US-342-1522: Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus Infection (clinicaltrials.gov) - Sep 25, 2017
P3, N=119, Completed, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||||| sofosbuvir/velpatasvir / Generic mfg.
Enrollment open, Trial initiation date: Lung Transplant HCV, Pilot Study (clinicaltrials.gov) - Sep 25, 2017
P, N=20, Recruiting, Sponsor: Marcelo Cypel
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Jun 2017 --> Sep 2017
- ||||||| sofosbuvir/velpatasvir / Generic mfg.
Trial completion: Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen (clinicaltrials.gov) - Sep 7, 2017
P3, N=117, Completed, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting | Initiation date: Jun 2017 --> Sep 2017 Active, not recruiting --> Completed
- ||||| sofosbuvir/velpatasvir / Generic mfg.
Enrollment closed: GS-US-342-1521: Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection (clinicaltrials.gov) - Aug 23, 2017
P3, N=125, Active, not recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | sofosbuvir/velpatasvir / Generic mfg.
New P4 trial: Generic VEL/SOF With or Without RBV for HIV/HCV Coinfected Patients (clinicaltrials.gov) - Aug 15, 2017
P4, N=178, Completed, Sponsor: National Taiwan University Hospital
- | sofosbuvir/velpatasvir / Generic mfg.
Enrollment open: Expanding the Pool in Orthotopic Heart Transplantation (clinicaltrials.gov) - Aug 14, 2017
P=N/A, N=100, Recruiting, Sponsor: University of Pittsburgh
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||| sofosbuvir/velpatasvir / Generic mfg.
Enrollment closed: GS-US-342-1518: Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV (clinicaltrials.gov) - Aug 11, 2017
P3, N=375, Active, not recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| sofosbuvir/velpatasvir / Generic mfg.
Trial completion: Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant (clinicaltrials.gov) - Aug 4, 2017
P2, N=79, Completed, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| sofosbuvir/velpatasvir / Generic mfg.
Enrollment open, Phase classification, Adherence: DASH: Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence (clinicaltrials.gov) - Jul 31, 2017
P=N/A, N=253, Recruiting, Sponsor: Proteus Digital Health, Inc.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Phase classification: P4 --> PN/A
- | sofosbuvir/velpatasvir / Generic mfg.
New P4 trial: A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic (clinicaltrials.gov) - Jul 31, 2017
P4, N=20, Not yet recruiting, Sponsor: Community Research Initiative of New England
- | sofosbuvir/velpatasvir / Generic mfg.
New trial: Expanding the Pool in Orthotopic Heart Transplantation (clinicaltrials.gov) - Jul 19, 2017
P=N/A, N=100, Not yet recruiting, Sponsor: University of Pittsburgh
- | sofosbuvir/velpatasvir / Generic mfg.
New P4 trial, Post-transplantation: Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment (clinicaltrials.gov) - Jul 2, 2017
P4, N=10, Not yet recruiting, Sponsor: Duke University
- || sofosbuvir/velpatasvir / Generic mfg.
Trial primary completion date: GS-US-342-4062: Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease (clinicaltrials.gov) - Jun 14, 2017
P2, N=100, Recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting | Phase classification: P4 --> PN/A Trial primary completion date: Apr 2018 --> Jul 2018
- ledipasvir/sofosbuvir / Generic mfg.
Enrollment open: Sofosbuvir/Ledipasvir for Hepatitis C Genotype 1-6 in Patients With Transfusion-Dependent Thalassemia: An Open Label Trial (clinicaltrials.gov) - Jun 7, 2017
P4, N=10, Recruiting, Sponsor: Ala'a Sharara
Trial primary completion date: Apr 2018 --> Jul 2018 Not yet recruiting --> Recruiting
- sofosbuvir/velpatasvir / Generic mfg.
Trial primary completion date: Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation (clinicaltrials.gov) - Jun 1, 2017
P2, N=10, Recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Trial primary completion date: Oct 2017 --> Apr 2018
- | sofosbuvir/velpatasvir / Generic mfg.
Enrollment open: CHIP: Curing HCV in Incarcerated Patients (clinicaltrials.gov) - Jun 1, 2017
P4, N=100, Enrolling by invitation, Sponsor: San Francisco Department of Public Health
Trial primary completion date: Oct 2017 --> Apr 2018 Not yet recruiting --> Enrolling by invitation
- ||||| sofosbuvir/velpatasvir / Generic mfg.
New P4 trial, Adherence: DASH: Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence (clinicaltrials.gov) - May 24, 2017
P4, N=253, Not yet recruiting, Sponsor: Proteus Digital Health, Inc.
- |||| sofosbuvir/velpatasvir / Generic mfg.
Trial primary completion date: GS-US-342-1521: Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection (clinicaltrials.gov) - May 22, 2017
P3, N=125, Recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Enrolling by invitation Trial primary completion date: Jul 2017 --> Dec 2017
- || sofosbuvir/velpatasvir / Generic mfg.
Trial primary completion date: Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children With Chronic HCV Infection (clinicaltrials.gov) - May 18, 2017
P2, N=200, Recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Jul 2017 --> Dec 2017 Trial primary completion date: Oct 2018 --> Sep 2019
- || sofosbuvir/velpatasvir / Generic mfg.
Trial primary completion date: GS-US-342-4062: Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease (clinicaltrials.gov) - May 16, 2017
P2, N=100, Recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Oct 2018 --> Sep 2019 Trial primary completion date: Jul 2018 --> Apr 2018
- ||| ribavirin / Generic mfg., sofosbuvir/velpatasvir / Generic mfg.
Enrollment closed: GS-US-342-2097: Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and Cirrhosis (clinicaltrials.gov) - May 3, 2017
P2, N=204, Active, not recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Jul 2018 --> Apr 2018 Recruiting --> Active, not recruiting
- | sofosbuvir/velpatasvir / Generic mfg.
Enrollment open: Transplanting Hepatitis C Positive Organs (clinicaltrials.gov) - Apr 20, 2017
P4, N=32, Recruiting, Sponsor: Brigham and Women's Hospital
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||||| sofosbuvir/velpatasvir / Generic mfg.
Enrollment open: GS-US-342-1521: Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection (clinicaltrials.gov) - Apr 6, 2017
P3, N=125, Recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting